<code id='49EA5EC380'></code><style id='49EA5EC380'></style>
    • <acronym id='49EA5EC380'></acronym>
      <center id='49EA5EC380'><center id='49EA5EC380'><tfoot id='49EA5EC380'></tfoot></center><abbr id='49EA5EC380'><dir id='49EA5EC380'><tfoot id='49EA5EC380'></tfoot><noframes id='49EA5EC380'>

    • <optgroup id='49EA5EC380'><strike id='49EA5EC380'><sup id='49EA5EC380'></sup></strike><code id='49EA5EC380'></code></optgroup>
        1. <b id='49EA5EC380'><label id='49EA5EC380'><select id='49EA5EC380'><dt id='49EA5EC380'><span id='49EA5EC380'></span></dt></select></label></b><u id='49EA5EC380'></u>
          <i id='49EA5EC380'><strike id='49EA5EC380'><tt id='49EA5EC380'><pre id='49EA5EC380'></pre></tt></strike></i>

          Home / entertainment / fashion

          fashion


          fashion

          author:hotspot    Page View:6
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In